Phase II Study of Pegylated Liposomal Doxorubicin (Doxil) and Temsirolimus (Torisel) in Patients With Advanced Hepatocellular Cancer

Trial Profile

Phase II Study of Pegylated Liposomal Doxorubicin (Doxil) and Temsirolimus (Torisel) in Patients With Advanced Hepatocellular Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2013

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Temsirolimus (Primary)
  • Indications Liver cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 20 Jun 2011 Planned end date changed from Jul 2012 to May 2014 as reported by ClinicalTrials.gov.
    • 20 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top